HOME Top Market Reports Biosimulation Market by Product (Software, Molecular Simulation, In House, Contract Services), Application (Clinical Trials, PKPD, ADME), Delivery (Subscription, Ownership), End User (Biotech, Pharma Companies, CROs, Regulatory) - Global Forecast to 2022

Biosimulation Market by Product (Software, Molecular Simulation, In House, Contract Services), Application (Clinical Trials, PKPD, ADME), Delivery (Subscription, Ownership), End User (Biotech, Pharma Companies, CROs, Regulatory) - Global Forecast to 2022

By: marketsandmarkets.com
Publishing Date: January 2018
Report Code: HIT 3629

 

  Speak to Analyst Enquiry Before Buying Webinar
purchase report
download pdf  request for customisation


The biosimulation market is expected to reach USD 2.88 Billion by 2022 from USD 1.20 Billion in 2016 growing at a CAGR of 15.9% during the forecast period. The base year considered for the study is 2016 and the forecast period is from 2017 to 2022.

The objectives of this study are as follows:

  • To define, describe, segment and forecast the global biosimulation market on the basis of product & service, application, delivery model, end user, and region
  • To provide detailed information regarding the major factors influencing the growth of the market (drivers, restraints, opportunities, challenges, and market-specific trends)
  • To analyze micromarkets with respect to individual growth trends, future prospects, and contributions to the overall market
  • To analyze the opportunities in the market for stakeholders and provide details of competitive landscape for market leaders
  • To forecast the size of the market segments with respect to four main regions, namely, North America, Europe, Asia, and the Rest of the World (RoW)
  • To profile key players and comprehensively analyze their market shares and core competencies
  • To track and analyze competitive developments such as agreements, partnerships, and collaborations; acquisitions; and product launches & upgrades; expansions; and R&D activities in the global biosimulation market

Research Methodology

The study estimates the biosimulation market size for 2017 and projects its demand till 2022. In the primary research process, various sources from both demand side and supply side were interviewed to obtain qualitative and quantitative information for the report. Primary sources from the demand side include various industry CEOs, vice presidents, marketing directors, technology and innovation directors, and related key executives from the various players in the biosimulation market. For the market estimation process, both top-down and bottom-up approaches were used to estimate and validate the market size of the biosimulation market as well as to estimate the market size of various other dependent submarkets. All possible parameters that affect the market covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. This data was consolidated and added to detailed inputs and analysis from MarketsandMarkets and presented in this report.

Biosimulation Market

To know about the assumptions considered for the study, download the pdf brochure

The biosimulation market is highly competitive with the presence of various players. Some of the major players operating in the market are Certara (US), Simulation Plus (US), Dassault Systθmes (France), Schrφdinger (US), ACD/Labs (Canada), Chemical Computing Group (Canada), Physiomics (UK), Evidera (US), In silico biosciences (US), INOSIM Software (Germany), Insilico Biotechnology (Germany), LeadInvent Technologies (India), Rosa (US), Nuventra Pharma (US), and Genedata (Switzerland).

Target Audience for this Report:

  • Biosimulation product manufacturers, vendors, and distributors
  • Market research and consulting companies
  • Regulatory authorities
  • Associations related to pharmaceutical and biotechnology research
  • Biotechnology and pharmaceutical companies
  • Academic and government research institutes
  • Contract research organizations (CROs)

Scope of the Report

This report categorizes the biosimulation market into following segments and subsegments:

By Product & Service

  • Software
    • Molecular Modeling and Simulation Software
    • PBPK Modeling and Simulation Software
    • PK/PD Modeling and Simulation Software
    • Trial Design Software
    • Toxicity Prediction Software
    • Other Biosimulation Software
  • Services
    • In-house Services
    • Contract Services

By Application

  • Drug Development
    • Preclinical Testing
      • PK/PD
      • ADME/TOX
    • Clinical Trials
  • Drug Discovery    
    • Target Identification and Validation
    • Lead Identification and Optimization
  • Other Applications              

By Delivery Model

  • Subscription Models
  • Ownership Models

By End User

  • Pharmaceutical and Biotechnology Companies
  • Research Institutes
  • Contract Research Organizations
  • Regulatory Authorities
  • Other End Users

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • RoE
  • Asia
  • Rest of the World (RoW)

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company‘s specific needs.

The following customization options are available for this report.

Company Information

Detailed analysis and profiling of additional market players (up to 5)

Table of Contents

1 Introduction (Page No. - 17)
    1.1 Objectives of the Study
    1.2 Market Definition
    1.3 Market Scope
           1.3.1 Markets Covered
           1.3.2 Years Considered for the Study
    1.4 Currency
    1.5 Limitations
    1.6 Market Stakeholders

2 Research Methodology (Page No. - 20)
    2.1 Research Data
    2.2 Secondary Data
           2.2.1 Secondary Source
    2.3 Primary Data
           2.3.1 Primary Sources
           2.3.2 Key Industry Insights
    2.4 Market Size Estimation
    2.5 Market Breakdown and Data Triangulation
    2.6 Assumptions for the Study

3 Executive Summary (Page No. - 28)

4 Premium Insights (Page No. - 32)
    4.1 Biosimulation Market Overview
    4.2 Biosimulation Software Market, By Type
    4.3 Geographic Analysis: Biosimulation Market in Europe, By End User and Country
    4.4 Biosimulation Drug Developement Market, By Type

5 Market Overview (Page No. - 35)
    5.1 Introduction
    5.2 Market Dynamics
           5.2.1 Drivers
                    5.2.1.1 Increase in R&D Investments in the Pharmaceutical and Biotechnology Industries
                    5.2.1.2 Growing Adoption of Biosimulation Software By Regulatory Bodies
                    5.2.1.3 Technologically Advanced Qsp Systems
                    5.2.1.4 Need to Curtail Drug Discovery and Development Costs
                    5.2.1.5 Growth in the Biologics and Biosimilars Markets
           5.2.2 Restraint
                    5.2.2.1 Lack of Standardization
           5.2.3 Opportunities
                    5.2.3.1 Emerging Applications
                    5.2.3.2 Increased Use of Personalized Medicine
                    5.2.3.3 Use of Biosimulation Solution for Pediatric Drug Development
           5.2.4 Challenges
                    5.2.4.1 Difficulty in Matching the Complexity of Biological Systems and Processes
                    5.2.4.2 Shortage of Biosimulation and Modeling Experts

6 Biosimulation Market, By Product & Service (Page No. - 40)
    6.1 Introduction
    6.2 Software
           6.2.1 PK/PD Modeling and Simulation Software
           6.2.2 Molecular Modeling and Simulation Software
           6.2.3 Pbpk Modeling and Simulation Software
           6.2.4 Toxicity Prediction Software
           6.2.5 Trial Design Software
           6.2.6 Other Biosimulation Software
    6.3 Services
           6.3.1 In-House Services
           6.3.2 Contract Services

7 Biosimulation Market, By Application (Page No. - 58)
    7.1 Introduction
    7.2 Drug Development
           7.2.1 Preclinical Testing
                    7.2.1.1 PK/PD
                    7.2.1.2 ADME/TOX
           7.2.2 Clinical Trials
    7.3 Drug Discovery
           7.3.1 Target Identification and Validation
           7.3.2 Lead Identification and Optimization
    7.4 Other Applications

8 Biosimulation Market, By Delivery Model (Page No. - 76)
    8.1 Introduction
    8.2 Subscription Models
    8.3 Ownership Models

9 Biosimulation Market, By End User (Page No. - 82)
    9.1 Introduction
    9.2 Pharmaceutical & Biotechnology Companies
    9.3 Research Institutes
    9.4 Contract Research Organizations
    9.5 Regulatory Authorities
    9.6 Other End Users

10 Biosimulation Market, By Region (Page No. - 94)
     10.1 Introduction
     10.2 North America
             10.2.1 US
             10.2.2 Canada
     10.3 Europe
             10.3.1 Germany
             10.3.2 UK
             10.3.3 France
             10.3.4 Rest of Europe (RoE)
     10.4 Asia
     10.5 Rest of the World (RoW)

11 Competitive Landscape (Page No. - 140)
     11.1 Overview
     11.2 Market Ranking Analysis, 2016
     11.3 Competitive Scenario
             11.3.1 Product Launches and Approvals
             11.3.2 Agreements, Partnerships, and Collaborations
             11.3.3 Acquisitions
             11.3.4 Expansions

12 Company Profiles (Page No. - 144)
(Overview, Products Offered, Product Offering Scorecard, Business Strategy Scorecard, Recent Developments)*
     12.1 Certara
     12.2 Simulation Plus
     12.3 Dassault Systθmes
     12.4 Schrφdinger
     12.5 Advanced Chemistry Development
     12.6 Chemical Computing Group
     12.7 Rosa
     12.8 Genedata
     12.9 Physiomics
     12.10 Evidera
     12.11 In Silico Biosciences
     12.12 Leadinvent Technologies
     12.13 Inosim Software
     12.14 Nuventra Pharma
     12.15 Insilico Biotechnology

*Details on Marketsandmarkets View, Overview, Products Offered, Product Offering Scorecard, Business Strategy Scorecard, and Recent Developments Might Not Be Captured in Case of Unlisted Companies.

13 Appendix (Page No. - 171)
     13.1 Insights Form Industry Experts
     13.2 Discussion Guide
     13.3 Knowledge Store: Marketsandmarkets’ Subscription Portal
     13.4 Introducing RT: Real-Time Market Intelligence
     13.5 Available Customizations
     13.6 Related Reports
     13.7 Author Details


List of Tables (187 Tables)

Table 1 Biosimulation Market, By Product & Service, 2015–2022 (USD Million)
Table 2 Biosimulation Software Market, By Type, 2015–2022 (USD Million)
Table 3 Biosimulation Software Market, By Region, 2015–2022 (USD Million)
Table 4 North America: Biosimulation Software Market, By Country, 2015–2022 (USD Million)
Table 5 Europe: Biosimulation Software Market, By Country, 2015–2022 (USD Million)
Table 6 PK/PD Modeling and Simulation Software Market, By Region, 2015–2022 (USD Million)
Table 7 North America: PK/PD Modeling and Simulation Software Market, By Country, 2015–2022 (USD Million)
Table 8 Europe: PK/PD Modeling and Simulation Software Market, By Country, 2015–2022 (USD Million)
Table 9 Molecular Modeling and Simulation Software Market, By Region, 2015–2022 (USD Million
Table 10 North America: Molecular Modeling and Simulation Software Market, By Country, 2015–2022 (USD Million)
Table 11 Europe: Molecular Modeling and Simulation Software Market, By Country, 2015–2022 (USD Million)
Table 12 Pbpk Modeling and Simulation Software Market, By Region, 2015–2022 (USD Million)
Table 13 North America: Pbpk Modeling and Simulation Software Market, By Country, 2015–2022 (USD Million)
Table 14 Europe: Pbpk Modeling and Simulation Software Market, By Country, 2015–2022 (USD Million)
Table 15 Toxicity Prediction Software Market, By Region, 2015–2022 (USD Million)
Table 16 North America: Toxicity Prediction Software Market, By Country, 2015–2022 (USD Million)
Table 17 Europe: Toxicity Prediction Software Market, By Country, 2015–2022 (USD Million)
Table 18 Trial Design Software Market, By Region, 2015–2022 (USD Million)
Table 19 North America: Trial Design Software Market, By Country, 2015–2022 (USD Million)
Table 20 Europe: Trial Design Software Market, By Country, 2015–2022 (USD Million)
Table 21 Other Biosimulation Software Market, By Region, 2015–2022 (USD Million)
Table 22 North America: Other Biosimulation Software Market, By Country, 2015–2022 (USD Million)
Table 23 Europe: Other Biosimulation Software Market, By Country, 2015–2022 (USD Million)
Table 24 Biosimulation Services Market, By Type, 2015–2022 (USD Million)
Table 25 Biosimulation Services Market, By Region, 2015–2022 (USD Million)
Table 26 North America: Biosimulation Services Market, By Country, 2015–2022 (USD Million)
Table 27 Europe: Biosimulation Services Market, By Country, 2015–2022 (USD Million)
Table 28 In-House Biosimulation Services Market, By Region, 2015–2022 (USD Million)
Table 29 North America: In-House Biosimulation Services Market, By Country, 2015–2022 (USD Million)
Table 30 Europe: In-House Biosimulation Services Market, By Country, 2015–2022 (USD Million)
Table 31 Contract Biosimulation Services Market, By Region, 2015–2022 (USD Million)
Table 32 North America: Contract Biosimulation Services Market, By Country, 2015–2022 (USD Million)
Table 33 Europe: Contract Biosimulation Services Market, By Country, 2015–2022 (USD Million)
Table 34 Biosimulation Market, By Application, 2015–2022 (USD Million)
Table 35 Biosimulation Market for Drug Development, By Type, 2015–2022 (USD Million)
Table 36 Biosimulation Market for Drug Development, By Region, 2015–2022 (USD Million)
Table 37 North America: Biosimulation Market for Drug Development, By Country, 2015–2022 (USD Million)
Table 38 Europe: Biosimulation Market for Drug Development, By Country, 2015–2022 (USD Million)
Table 39 Biosimulation Market for Preclinical Testing, By Type, 2015–2022 (USD Million)
Table 40 Biosimulation Market for Preclinical Testing, By Region, 2015–2022 (USD Million )
Table 41 North America: Biosimulation Market for Preclinical Testing, By Country, 2015–2022 (USD Million)
Table 42 Europe: Biosimulation Market for Preclinical Testing, By Country, 2015–2022 (USD Million)
Table 43 Biosimulation Market for PK/PD, By Region, 2015–2022 (USD Million)
Table 44 North America: Biosimulation Market for PK/PD, By Country, 2015–2022 (USD Million)
Table 45 Europe: Biosimulation Market for PK/PD, By Country, 2015–2022 (USD Million)
Table 46 Biosimulation Market for ADME/TOX, By Region, 2015–2022 (USD Million)
Table 47 North America: Biosimulation Market for ADME/TOX, By Country, 2015–2022 (USD Million)
Table 48 Europe: Biosimulation Market for ADME/TOX, By Country, 2015–2022 (USD Million)
Table 49 Biosimulation Market for Clinical Trials, By Region, 2015–2022 (USD Million)
Table 50 North America: Biosimulation Market for Clinical Trials, By Country, 2015–2022 (USD Million)
Table 51 Europe: Biosimulation Market for Clinical Trials, By Country, 2015–2022 (USD Million)
Table 52 Biosimulation Market for Drug Discovery, By Type, 2015–2022 (USD Million )
Table 53 Biosimulation Market for Drug Discovery, By Region, 2015–2022 (USD Million)
Table 54 North America: Biosimulation Market for Drug Discovery, By Country, 2015–2022 (USD Million)
Table 55 Europe: Biosimulation Market for Drug Discovery, By Country, 2015–2022 (USD Million)
Table 56 Biosimulation Market for Target Identification and Optimization, By Region, 2015–2022 (USD Million)
Table 57 North America: Biosimulation Market for Target Identification and Validation, By Country, 2015–2022 (USD Million)
Table 58 Europe: Biosimulation Market for Target Identification and Validation, By Country, 2015–2022 (USD Million)
Table 59 Biosimulation Market for Lead Identification and Optimization, By Region, 2015–2022 (USD Million)
Table 60 North America: Biosimulation Market for Lead Identification and Optimization, By Country, 2015–2022 (USD Million)
Table 61 Europe: Biosimulation Market for Lead Identification and Optimization, By Country, 2015–2022 (USD Million)
Table 62 Biosimulation Market for Other Applications, By Region, 2015–2022 (USD Million )
Table 63 North America: Biosimulation Market for Other Applications, By Country, 2015–2022 (USD Million)
Table 64 Europe: Biosimulation Market for Other Applications, By Country, 2015–2022 (USD Million)
Table 65 Global Biosimulation Market, By Delivery Model, 2015–2022 (USD Million)
Table 66 Global Biosimulation Market for Subscription Models, By Region, 2015–2022 (USD Million)
Table 67 North America: Biosimulation Market for Subscription Models, By Country, 2015–2022 (USD Million)
Table 68 Europe: Biosimulation Market for Subscription Models, By Country, 2015–2022 (USD Million)
Table 69 Global Biosimulation Market for Ownership Models, By Region, 2015–2022 (USD Million)
Table 70 North America: Biosimulation Market for Ownership Models, By Country, 2015–2022 (USD Million)
Table 71 Europe: Biosimulation Market for Ownership Models, By Country, 2015–2022 (USD Million)
Table 72 Biosimulation Market, By End User, 2015–2022 (USD Million)
Table 73 Biosimulation Market for Pharmaceutical & Biotechnology Companies, By Region, 2015–2022 (USD Million)
Table 74 North America: Biosimulation Market for Pharmaceutical & Biotechnology Companies, By Country, 2015–2022 (USD Million)
Table 75 Europe: Biosimulation Market for Pharmaceutical & Biotechnology Companies, By Country, 2015–2022 (USD Million)
Table 76 Biosimulation Market for Research Institutes, By Region, 2015–2022 (USD Million)
Table 77 North America: Biosimulation Market for Research Institutes, By Country, 2015–2022 (USD Million)
Table 78 Europe: Biosimulation Market for Research Institutes, By Country, 2015–2022 (USD Million)
Table 79 Biosimulation Market for Contract Research Organizations, By Region, 2015–2022 (USD Million)
Table 80 North America: Biosimulation Market for Contract Research Organizations, By Country, 2015–2022 (USD Million)
Table 81 Europe: Biosimulation Market for Contract Research Organizations, By Country, 2015–2022 (USD Million)
Table 82 Biosimulation Market for Regulatory Authorities, By Region, 2015–2022 (USD Million)
Table 83 North America: Biosimulation Market for Regulatory Authorities, By Country, 2015–2022 (USD Million)
Table 84 Europe: Biosimulation Market for Regulatory Authorities, By Country, 2015–2022 (USD Million)
Table 85 Biosimulation Market for Other End Users, By Region, 2015–2022 (USD Million)
Table 86 North America: Biosimulation Market for Other End Users, By Country, 2015–2022 (USD Million)
Table 87 Europe: Biosimulation Market for Other End Users, By Country, 2015–2022 (USD Million)
Table 88 Biosimulation Market, By Region, 2015–2022 (USD Million)
Table 89 North America Biosimulation Market, By Country, 2015–2022 (USD Million)
Table 90 North America: Biosimulation Market, By Product & Service, 2015–2022 (USD Million)
Table 91 North America: Biosimulation Software Market, By Type, 2015–2022 (USD Million)
Table 92 North America: Biosimulation Services Market, By Type, 2015–2022 (USD Million)
Table 93 North America: Biosimulation Market, By Application, 2015–2022 (USD Million)
Table 94 North America: Biosimulation Market for Drug Development Applications, By Type, 2015–2022 (USD Million)
Table 95 North America: Biosimulation Market for Preclinical Testing, By Type, 2015–2022 (USD Million)
Table 96 North America: Biosimulation Market for Drug Discovery Applications, By Type, 2015–2022 (USD Million)
Table 97 North America: Biosimulation Market, By Delivery Model, 2015–2022 (USD Million)
Table 98 North America: Biosimulation Market, By End User, 2015–2022 (USD Million)
Table 99 US: Biosimulation Market, By Product & Service, 2015–2022 (USD Million)
Table 100 US: Biosimulation Software Market, By Type, 2015–2022 (USD Million)
Table 101 US: Biosimulation Services Market, By Type, 2015–2022 (USD Million)
Table 102 US: Biosimulation Market, By Application, 2015–2022 (USD Million)
Table 103 US: Biosimulation Market for Drug Development Applications, By Type, 2015–2022 (USD Million)
Table 104 US: Biosimulation Market for Preclinical Testing, By Type, 2015–2022 (USD Million)
Table 105 US: Biosimulation Market for Drug Discovery Applications, By Type, 2015–2022 (USD Million)
Table 106 US: Biosimulation Market, By Delivery Model, 2015–2022 (USD Million)
Table 107 US: Biosimulation Market, By End User, 2015–2022 (USD Million)
Table 108 Canada: Biosimulation Market, By Product & Service, 2015–2022 (USD Million)
Table 109 Canada: Biosimulation Software Market, By Type, 2015–2022 (USD Million)
Table 110 Canada: Biosimulation Services Market, By Type, 2015–2022 (USD Million)
Table 111 Canada: Biosimulation Market, By Application, 2015–2022 (USD Million)
Table 112 Canada: Biosimulation Market for Drug Development Applications, By Type, 2015–2022 (USD Million)
Table 113 Canada: Biosimulation Market for Preclinical Testing, By Type, 2015–2022 (USD Million)
Table 114 Canada: Biosimulation Market for Drug Discovery Applications, By Type, 2015–2022 (USD Million)
Table 115 Canada: Biosimulation Market, By Delivery Model, 2015–2022 (USD Million)
Table 116 Canada: Biosimulation Market, By End User, 2015–2022 (USD Million)
Table 117 Europe: Pharmaceutical R&D Expenditure, By Country, 2015
Table 118 Europe: Biosimulation Market, By Country, 2015–2022 (USD Million)
Table 119 Europe: Biosimulation Market, By Product & Service, 2015–2022 (USD Million)
Table 120 Europe: Biosimulation Software Market, By Type, 2015–2022 (USD Million)
Table 121 Europe: Biosimulation Services Market, By Type, 2015–2022 (USD Million)
Table 122 Europe: Biosimulation Market, By Application, 2015–2022 (USD Million)
Table 123 Europe: Biosimulation Market for Drug Development Applications, By Type, 2015–2022 (USD Million)
Table 124 Europe: Biosimulation Market for Preclinical Testing, By Type, 2015–2022 (USD Million)
Table 125 Europe: Biosimulation Market for Drug Discovery Applications, By Type, 2015–2022 (USD Million)
Table 126 Europe: Biosimulation Market, By Delivery Model, 2015–2022 (USD Million)
Table 127 Europe: Biosimulation Market, By End User, 2015–2022 (USD Million)
Table 128 Biotechnology Industry in Germany (2009 vs 2016)
Table 129 Germany: Biosimulation Market, By Product & Service, 2015–2022 (USD Million)
Table 130 Germany: Biosimulation Software Market, By Type, 2015–2022 (USD Million)
Table 131 Germany: Biosimulation Services Market, By Type, 2015–2022 (USD Million)
Table 132 Germany: Biosimulation Market, By Application, 2015–2022 (USD Million)
Table 133 Germany: Biosimulation Market for Drug Development Applications, By Type, 2015–2022 (USD Million)
Table 134 Germany: Biosimulation Market for Preclinical Testing, By Type, 2015–2022 (USD Million)
Table 135 Germany: Biosimulation Market for Drug Discovery Applications, By Type, 2015–2022 (USD Million)
Table 136 Germany: Biosimulation Market, By Delivery Model, 2015–2022 (USD Million)
Table 137 Germany: Biosimulation Market, By End User, 2015–2022 (USD Million)
Table 138 UK: Biosimulation Market, By Product & Service, 2015–2022 (USD Million)
Table 139 UK: Biosimulation Software Market, By Type, 2015–2022 (USD Million)
Table 140 UK: Biosimulation Services Market, By Type, 2015–2022 (USD Million)
Table 141 UK: Biosimulation Market, By Application, 2015–2022 (USD Million)
Table 142 UK: Biosimulation Market for Drug Development Applications, By Type, 2015–2022 (USD Million)
Table 143 UK: Biosimulation Market for Preclinical Testing, By Type, 2015–2022 (USD Million)
Table 144 UK: Biosimulation Market for Drug Discovery Applications, By Type, 2015–2022 (USD Million)
Table 145 UK: Biosimulation Market, By Delivery Model, 2015–2022 (USD Million)
Table 146 UK: Biosimulation Market, By End User, 2015–2022 (USD Million)
Table 147 France: Biosimulation Market, By Product & Service, 2015–2022 (USD Million)
Table 148 France: Biosimulation Software Market, By Type, 2015–2022 (USD Million)
Table 149 France: Biosimulation Services Market, By Type, 2015–2022 (USD Million)
Table 150 France: Biosimulation Market, By Application, 2015–2022 (USD Million)
Table 151 France: Biosimulation Market for Drug Development Applications, By Type, 2015–2022 (USD Million)
Table 152 France: Biosimulation Market for Preclinical Testing, By Type, 2015–2022 (USD Million)
Table 153 France: Biosimulation Market for Drug Discovery Applications, By Type, 2015–2022 (USD Million)
Table 154 France: Biosimulation Market, By Delivery Model, 2015–2022 (USD Million)
Table 155 France: Biosimulation Market, By End User, 2015–2022 (USD Million)
Table 156 RoE: Biosimulation Market, By Product & Service, 2015–2022 (USD Million)
Table 157 RoE: Biosimulation Software Market, By Type, 2015–2022 (USD Million)
Table 158 RoE: Biosimulation Services Market, By Type, 2015–2022 (USD Million)
Table 159 RoE: Biosimulation Market, By Application, 2015–2022 (USD Million)
Table 160 RoE: Biosimulation Market for Drug Development Applications, By Type, 2015–2022 (USD Million)
Table 161 RoE: Biosimulation Market for Preclinical Testing, By Type, 2015–2022 (USD Million)
Table 162 RoE: Biosimulation Market for Drug Discovery Applications, By Type, 2015–2022 (USD Million)
Table 163 RoE: Biosimulation Market, By Delivery Model, 2015–2022 (USD Million)
Table 164 RoE: Biosimulation Market, By End User, 2015–2022 (USD Million)
Table 165 Asia: Biosimulation Market, By Product & Service, 2015–2022 (USD Million)
Table 166 Asia: Biosimulation Software Market, By Type, 2015–2022 (USD Million)
Table 167 Asia: Biosimulation Services Market, By Type, 2015–2022 (USD Million)
Table 168 Asia: Biosimulation Market, By Application, 2015–2022 (USD Million)
Table 169 Asia: Biosimulation Market for Drug Development Applications, By Type, 2015–2022 (USD Million)
Table 170 Asia: Biosimulation Market for Preclinical Testing, By Type, 2015–2022 (USD Million)
Table 171 Asia: Biosimulation Market for Drug Discovery Applications, By Type, 2015–2022 (USD Million)
Table 172 Asia: Biosimulation Market, By Delivery Model, 2015–2022 (USD Million)
Table 173 Asia: Biosimulation Market, By End User, 2015–2022 (USD Million)
Table 174 RoW: Biosimulation Market, By Product & Service, 2015–2022 (USD Million)
Table 175 RoW: Biosimulation Software Market, By Type, 2015–2022 (USD Million)
Table 176 RoW: Biosimulation Services Market, By Type, 2015–2022 (USD Million)
Table 177 RoW: Biosimulation Market, By Application, 2015–2022 (USD Million)
Table 178 RoW: Biosimulation Market for Drug Development Applications, By Type, 2015–2022 (USD Million)
Table 179 RoW: Biosimulation Market for Preclinical Testing, By Type, 2015–2022 (USD Million)
Table 180 RoW: Biosimulation Market for Drug Discovery Applications, By Type, 2015–2022 (USD Million)
Table 181 RoW: Biosimulation Market, By Delivery Model, 2015–2022 (USD Million)
Table 182 RoW: Biosimulation Market, By End User, 2015–2022 (USD Million)
Table 183 Rank of Companies in the Global Biosimulation Market, 2016
Table 184 Product Launches and Approvals
Table 185 Agreements, Partnerships, and Collaborations
Table 186 Acquisitions
Table 187 Expansions


List of Figures (28 Figures)

Figure 1 Research Design: Biosimulation Market
Figure 2 Break Down of Primary Interviews: By Company, Designation, and Region
Figure 3 Market Estimation: Bottom-Up Approach
Figure 4 Global Market Size of the Biosimulation Market: Top-Down Approach
Figure 5 Data Triangulation Methodology
Figure 6 Biosimulation Software to Dominate the Biosimulation Market in 2017 and 2022
Figure 7 Drug Development Segment to Dominate the Biosimulation Applications Market in 2017 and 2022
Figure 8 Subscription Model Segment to Dominate the Delivery Model Segment of Biosimulation Market in 2017 and 2022
Figure 9 Pharmaceutical & Biotechnology Companies to Dominate the Biosimulation End-User Market
Figure 10 Europe to Witness High Growth During the Forecast Period (2017–2022)
Figure 11 Increase in R&D Investments in the Pharmaceutical and Biotechnology Industries to Drive the Growth of the Market
Figure 12 PK/PD Modeling and Simulation Software to Account for the Largest Market Size in 2017 and 2022
Figure 13 Pharmaceutical & Biotechnology Companies to Account for the Largest Share of the Biosimulation Market in Europe in 2017
Figure 14 Preclinical Testing to Witness High Growth From 2017 to 2022
Figure 15 Biosimulation Market: Drivers, Restraints, Opportunities, and Challenges
Figure 16 Software Segment to Dominate the Biosimulation Market in 2017
Figure 17 Drug Development Segment to Dominate the Biosimulation Market During the Forecast Period
Figure 18 Ownership Models Segment to Offer Significant Growth Opportunities During the Forecast Period
Figure 19 Biosimulation Market, By End User, 2017 vs 2022 (USD Million)
Figure 20 Biosimulation Market in Europe to Witness the Highest Growth Rate During the Forecast Period
Figure 21 North America: Biosimulation Market Snapshot
Figure 22 Europe: Biosimulation Market Snapshot
Figure 23 Asia: Biosimulation Market Snapshot
Figure 24 RoW: Biosimulation Market Snapshot
Figure 25 Market Evolution Framework
Figure 26 Simulation PlUS: Company Snapshot (2016)
Figure 27 Dassault Systθmes: Company Snapshot (2016)
Figure 28 Physiomics : Company Snapshot (2017)

The global biosimulation market is projected to reach USD 2.88 Billion by 2022 from USD 1.38 Billion in 2017, at a CAGR of 15.9%. Factors such as increase in R&D investments in the pharmaceutical and biotechnology industries, growing adoption of biosimulation software by regulatory bodies, technologically advanced QSP systems, need to curtail drug discovery and development costs, and growth in the biologics and biosimilars markets are driving the growth of the market.

The report segments the global biosimulation market into by product & service, application, delivery model, end user, and region.

Based on product & service, the biosimulation market is segmented into software and services. The biosimulation software segment is expected to account for the largest market share in 2017. The high growth in this segment is attributed to the growing adoption of biosimulation software by pharmaceutical and research organizations and the increasing R&D investment for pharmaceutical research.

Based on application, the biosimulation market is segmented into drug discovery, drug development, and other applications (nutraceuticals, and agri-food production). The drug development segment is estimated to account for the largest market share in 2017. Biosimulation solutions help to reduce the time and cost of the drug development process by screening out flawed NCEs that have a higher probability of failure due to toxicity and poor PK/PD properties. These factors are expected to increase the adoption of biosimulation software in the drug development process and are supporting the growth of this application segment.

Based on delivery model, the biosimulation market is segmented into ownership models and subscription models. The subscription models segment is estimated to account for the largest market share in 2017. The large share of the subscription models segment is attributed to the advantages associated with these models such as cost-effectiveness, interoperability, and flexibility.

Based on end user, the biosimulation market is segmented into research institutes, pharmaceutical and biotechnology companies, contract research organizations (CROs), regulatory authorities, and other end users (consulting firms, defense research and development organizations, nutraceutical companies, and food and agricultural companies). In 2017, pharmaceutical and biotechnology companies are expected to form the largest share in 2017, and is projected to register the highest CAGR during the forecast period. Increased R&D budgets of pharmaceutical and biotechnology companies and increasing adoption of inorganic growth strategies by different biosimulation service providers are likely to boost the adoption of biosimulation solutions in the pharmaceuticals and biotechnology industry.

Biosimulation Market

The market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). The dominance of the North American market is attributed to factors such as growth in the biotechnology and pharmaceutical industry, a large number of ongoing drug development processes, increased use of personalized medicine, and increasing R&D expenditure by pharmaceutical and biotechnology companies.

While the emerging applications, increased use of personalized medicine, and use of biosimulation solution for pediatric drug development represents significant growth opportunities, market growth may be hindered due to lack of standardization for biosimulation solutions. The biosimulation market is highly competitive with the presence of several big and small players. Prominent players in this market include Certara (US), Simulations Plus (US), Dassault Systθmes (France), Schrφdinger (US), ACD/Labs (Canada), Chemical Computing Group (Canada), Physiomics (UK), Evidera (US), In silico biosciences (US), INOSIM Software (Germany), Insilico Biotechnology (Germany), LeadInvent Technologies (India), Rosa (US), Nuventra Pharma (US), and Genedata (Switzerland).

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Please visit https://www.marketsandmarkets.com/knowledge-process-outsourcing-services.asp to specify your custom Research Requirement

Connect With Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441
UK : 44-800-368-9399

Search reports



Access reports on all high
growth Healthcare IT Markets on KnowledgeStore
Request Demo